Phase 2 Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 70 years old
- People who are generally well enough to carry out daily activities with little or no limitation (as measured by a standard medical scale called ECOG, with a score of 0 or 1)
- People who have had, or are scheduled to have, surgery to remove the bladder (with lymph node removal) or surgery to remove the kidney and ureter
- People whose surgical tissue sample has confirmed a specific type of bladder or urinary tract cancer called transitional cell (urothelial) carcinoma
- People whose cancer has been staged at a specific level (pT2–4a, N0–2, M0), meaning the cancer has grown into or through the bladder muscle but has not spread to distant parts of the body (confirm with trial site for exact staging details)
- People whose surgeon was able to remove all visible cancer with no cancer cells left at the edges of the removed tissue, confirmed by a CT or MRI scan of the chest, abdomen, and pelvis within 4 weeks before joining the trial
- People whose blood and organ function results fall within acceptable ranges in blood tests taken within 28 days before starting treatment — including healthy enough levels of white blood cells, red blood cells, platelets, liver enzymes, and kidney function (confirm with trial site for specific values)
- People who are able to understand the trial information and provide written consent to participate
Who may not be able to join:
- People who have received any approved cancer treatment within 3 weeks before enrolling in the trial
- People who have taken part in another clinical trial involving a treatment within 28 days before enrolling
- People who have had a different type of cancer (other than this urinary tract cancer) within the past 5 years
- People who have health conditions that make chemotherapy unsafe, such as reduced kidney function, hearing problems, or poor bone marrow function
- People who have had a severe allergic reaction or have a known reason they cannot take the chemotherapy drugs cisplatin or gemcitabine
- People with active or uncontrolled infections, including HIV, hepatitis B, hepatitis C, or tuberculosis
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yung Na, PHD, The University of Hong Kong
Phone: 22554852
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
the radiational disease-free survival (rDFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.